The impact of Astragaloside IV on the inflammatory response and gut microbiota in cases of acute lung injury is examined through the utilization of the PI3K/AKT/mTOR pathway
PLOS ONE · 02.07.2024 · 19 (7) · e0305058
DOI: 10.1371/journal.pone.0305058 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 02.07.2024. Verfasst von Cheng Luo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical College of traditional Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, China. Hauptthemen laut MEDLINE: Saponins, Triterpenes, Acute Lung Injury, TOR Serine-Threonine Kinases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Administration of Traditional Chinese Medicine Inheritance Studio Construction Project, Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
Objectives
Astragaloside IV (AS-IV) is a natural triterpenoid saponin compound with a variety of pharmacological effects, and several studies have clarified its anti-inflammatory effects, which may make it an effective alternative treatment against inflammation. In the study, we aimed to investigate whether AS-IV could attenuate the inflammatory response to acute lung injury and its mechanisms.
Methods
Different doses of AS-IV (20mg·kg -1 , 40mg·kg -1 , and 80mg·kg -1 ) were administered to the ALI rat model, followed by collection of serum and broncho alveolar lavage fluid (BALF) for examination of the inflammatory response, and HE staining of the lung and colon tissues, and interpretation of the potential molecular mechanisms by quantitative real-time PCR (qRT-PCR), Western blotting (WB). In addition, fecal samples from ALI rats were collected and analyzed by 16S rRNA sequencing.
Results
AS-IV decreased the levels of TNF-α, IL-6, and IL-1β in serum and BALF of mice with Acute lung injury (ALI). Lung and colon histopathology confirmed that AS-IV alleviated inflammatory infiltration, tissue edema, and structural changes. qRT-PCR and WB showed that AS-IV mainly improved inflammation by inhibiting the expression of PI3K, AKT and mTOR mRNA, and improved the disorder of intestinal microflora by increasing the number of beneficial bacteria and reducing the number of harmful bacteria.
Conclusion
AS-IV reduces the expression of inflammatory factors by inhibiting the PI3K/AKT/mTOR pathway and optimizes the composition of the gut microflora in AIL rats.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical College of traditional Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, China.
- Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Academy of Traditional Chinese Medicine, Affiliated Hospital of Hubei University of Traditional Chinese Medicine, Wuhan, China.
ORCID-Profile: Jia Ke
Förderung
- National Administration of Traditional Chinese Medicine Inheritance Studio Construction Project
- Natural Science Foundation of Hubei Province
Zitieren
APA
Luo, C., Ye, Y., Lv, A., Zuo, W., Yang, Y., Jiang, C., & Ke, J. (2024). The impact of Astragaloside IV on the inflammatory response and gut microbiota in cases of acute lung injury is examined through the utilization of the PI3K/AKT/mTOR pathway. PLOS ONE, 19(7), e0305058. https://doi.org/10.1371/journal.pone.0305058
Vancouver
Luo C, Ye Y, Lv A, Zuo W, Yang Y, Jiang C, et al. The impact of Astragaloside IV on the inflammatory response and gut microbiota in cases of acute lung injury is examined through the utilization of the PI3K/AKT/mTOR pathway. PLOS ONE. 2024;19(7):e0305058. doi:10.1371/journal.pone.0305058
BibTeX
@article{Luo2024,
author = {Luo, Cheng and Ye, Yuanhang and Lv, Anqi and Zuo, Wanzhao and Yang, Yi and Jiang, Cheng and Ke, Jia},
title = {The impact of Astragaloside IV on the inflammatory response and gut microbiota in cases of acute lung injury is examined through the utilization of the PI3K/AKT/mTOR pathway},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {7},
pages = {e0305058},
doi = {10.1371/journal.pone.0305058}
}
EUVIMED